Skip to main content
Top
Published in: Cancer Causes & Control 7/2017

01-07-2017 | Original paper

Racial differences in prostate cancer risk in young HIV-positive and HIV-negative men: a prospective cohort study

Authors: Anupriya Dutta, Hajime Uno, Alex Holman, David R. Lorenz, Dana Gabuzda

Published in: Cancer Causes & Control | Issue 7/2017

Login to get access

Abstract

Purpose

African American men have the highest incidence of prostate cancer among ethnic groups, and racial disparity is highest in younger men. Prostate cancer prevalence is rising in HIV-infected men due to improved survival on antiretroviral therapies, yet little is known about racial differences in prostate cancer risk by HIV-infection status and age.

Methods

This is a prospective cohort study of prostate cancer risk in 2,800 HIV-infected and -uninfected men who have sex with men (MSM) aged 40–70 years (22% African American) who were enrolled in the multicenter AIDS cohort study from 1996 to 2010. Poisson regression models were used to examine associations between race and HIV-infection status and prostate cancer risk among men aged 40–70, 40–55, and 56–70 years.

Results

Among men aged 40–70 years, incidence rates (IR) per 100,000 person-years were 169 among all men and 276 among African American HIV-infected men. Prostate cancer risk was similar by HIV-infection status (IRR 1.0, 95% CI 0.55–1.82), but nearly threefold higher in African Americans compared to non-African Americans in adjusted models (IRRs 2.66 and 3.22, 95% CIs 1.36–5.18 and 1.27–8.16 for all or HIV-infected men, respectively). Racial disparity in prostate cancer risk was greatest in African American men aged 40–55 years (adjusted IRR 3.31, 95% CI 1.19–9.22). Prostate cancer risk showed associations with family history of prostate cancer (p = 0.001), but not heavy smoking, androgen supplement use, or HIV-related factors.

Conclusions

Among MSM, African American HIV-positive and HIV-negative men aged 40–55 years have threefold increased risk of young-onset prostate cancer compared to non-African American men, highlighting the need to make informed decisions about screening in this population.
Literature
1.
go back to reference Schymura MJ, Sun L, Percy-Laurry A (2014) Prostate cancer collaborative stage data items—their definitions, quality, usage, and clinical implications: a review of SEER data for 2004–2010. Cancer 120(Suppl 23):3758–3770CrossRefPubMed Schymura MJ, Sun L, Percy-Laurry A (2014) Prostate cancer collaborative stage data items—their definitions, quality, usage, and clinical implications: a review of SEER data for 2004–2010. Cancer 120(Suppl 23):3758–3770CrossRefPubMed
2.
go back to reference Robbins HA, Shiels MS, Pfeiffer RM, Engels EA (2014) Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS 28:881–890CrossRefPubMedPubMedCentral Robbins HA, Shiels MS, Pfeiffer RM, Engels EA (2014) Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS 28:881–890CrossRefPubMedPubMedCentral
3.
go back to reference Coghill AE, Shiels MS, Suneja G, Engels EA (2015) Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol 33:2376–2383CrossRefPubMedPubMedCentral Coghill AE, Shiels MS, Suneja G, Engels EA (2015) Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol 33:2376–2383CrossRefPubMedPubMedCentral
4.
go back to reference Heslin KC, Gore JL, King WD, Fox SA (2008) Sexual orientation and testing for prostate and colorectal cancers among men in California. Med Care 46:1240–1248CrossRefPubMedPubMedCentral Heslin KC, Gore JL, King WD, Fox SA (2008) Sexual orientation and testing for prostate and colorectal cancers among men in California. Med Care 46:1240–1248CrossRefPubMedPubMedCentral
5.
go back to reference Riedel DJ, Cox ER, Stafford KA, Gilliam BL (2015) Clinical presentation and outcomes of prostate cancer in an urban cohort of predominantly African American, human immunodeficiency virus-infected patients. Urology 85:415–421CrossRefPubMed Riedel DJ, Cox ER, Stafford KA, Gilliam BL (2015) Clinical presentation and outcomes of prostate cancer in an urban cohort of predominantly African American, human immunodeficiency virus-infected patients. Urology 85:415–421CrossRefPubMed
6.
go back to reference DeSantis CE, Siegel RL, Sauer AG et al (2016) Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin 66:290–308CrossRefPubMed DeSantis CE, Siegel RL, Sauer AG et al (2016) Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin 66:290–308CrossRefPubMed
7.
go back to reference Ross RK, Pike MC, Coetzee GA et al (1998) Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 58:4497–4504PubMed Ross RK, Pike MC, Coetzee GA et al (1998) Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 58:4497–4504PubMed
8.
go back to reference Hughes L, Zhu F, Ross E et al (2012) Assessing the clinical role of genetic markers of early-onset prostate cancer among high-risk men enrolled in prostate cancer early detection. Cancer Epidemiol Biomark Prev 21:53–60CrossRef Hughes L, Zhu F, Ross E et al (2012) Assessing the clinical role of genetic markers of early-onset prostate cancer among high-risk men enrolled in prostate cancer early detection. Cancer Epidemiol Biomark Prev 21:53–60CrossRef
9.
go back to reference Marcus JL, Chao CR, Leyden WA et al (2014) Prostate cancer incidence and prostate-specific antigen testing among HIV-positive and HIV-negative men. J Acquir Immune Defic Syndr 66:495–502CrossRefPubMed Marcus JL, Chao CR, Leyden WA et al (2014) Prostate cancer incidence and prostate-specific antigen testing among HIV-positive and HIV-negative men. J Acquir Immune Defic Syndr 66:495–502CrossRefPubMed
10.
go back to reference Hsing AW, Sakoda LC, Chua S Jr (2007) Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 86:s843–s857PubMed Hsing AW, Sakoda LC, Chua S Jr (2007) Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 86:s843–s857PubMed
11.
go back to reference Silberstein J, Downs T, Lakin C, Kane CJ (2009) HIV and prostate cancer: a systematic review of the literature. Prostate Cancer Prostatic Dis 12:6–12CrossRefPubMed Silberstein J, Downs T, Lakin C, Kane CJ (2009) HIV and prostate cancer: a systematic review of the literature. Prostate Cancer Prostatic Dis 12:6–12CrossRefPubMed
12.
go back to reference Shiels MS, Goedert JJ, Moore RD, Platz EA, Engels EA (2010) Reduced risk of prostate cancer in U.S. Men with AIDS. Cancer Epidemiol Biomark Prev 19:2910–2915CrossRef Shiels MS, Goedert JJ, Moore RD, Platz EA, Engels EA (2010) Reduced risk of prostate cancer in U.S. Men with AIDS. Cancer Epidemiol Biomark Prev 19:2910–2915CrossRef
13.
go back to reference Robbins HA, Pfeiffer RM, Shiels MS, Li J, Hall HI, Engels EA (2015) Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst 107:dju503PubMedPubMedCentral Robbins HA, Pfeiffer RM, Shiels MS, Li J, Hall HI, Engels EA (2015) Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst 107:dju503PubMedPubMedCentral
14.
go back to reference Silverberg MJ, Chao C, Leyden WA et al (2011) HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomark Prev 20:2551–2559CrossRef Silverberg MJ, Chao C, Leyden WA et al (2011) HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomark Prev 20:2551–2559CrossRef
15.
go back to reference Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC (2009) Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr 52:203–208CrossRefPubMedPubMedCentral Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC (2009) Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr 52:203–208CrossRefPubMedPubMedCentral
16.
go back to reference Burgi A, Brodine S, Wegner S et al (2005) Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 104:1505–1511CrossRefPubMed Burgi A, Brodine S, Wegner S et al (2005) Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 104:1505–1511CrossRefPubMed
17.
go back to reference Crum NF, Spencer CR, Amling CL (2004) Prostate carcinoma among men with human immunodeficiency virus infection. Cancer 101:294–299CrossRefPubMed Crum NF, Spencer CR, Amling CL (2004) Prostate carcinoma among men with human immunodeficiency virus infection. Cancer 101:294–299CrossRefPubMed
18.
go back to reference Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S (2007) The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 165:1143–1153CrossRefPubMed Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S (2007) The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 165:1143–1153CrossRefPubMed
19.
go back to reference Pantanowitz L, Bohac G, Cooley TP, Aboulafia D, Dezube BJ (2008) Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study. BJU Int 101:1519–1523CrossRefPubMed Pantanowitz L, Bohac G, Cooley TP, Aboulafia D, Dezube BJ (2008) Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study. BJU Int 101:1519–1523CrossRefPubMed
21.
go back to reference Shiels MS, Engels EA (2017) Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS 12:6–11CrossRefPubMed Shiels MS, Engels EA (2017) Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS 12:6–11CrossRefPubMed
23.
go back to reference Lin DW, Porter M, Montgomery B (2009) Treatment and survival outcomes in young men diagnosed with prostate cancer: a population-based cohort study. Cancer 115:2863–2871CrossRefPubMedPubMedCentral Lin DW, Porter M, Montgomery B (2009) Treatment and survival outcomes in young men diagnosed with prostate cancer: a population-based cohort study. Cancer 115:2863–2871CrossRefPubMedPubMedCentral
24.
go back to reference Shteynshlyuger A, Andriole GL (2010) Prostate cancer: to screen or not to screen? Urol Clin N Am 37:1–9CrossRef Shteynshlyuger A, Andriole GL (2010) Prostate cancer: to screen or not to screen? Urol Clin N Am 37:1–9CrossRef
25.
26.
go back to reference Powell IJ, Vigneau FD, Bock CH, Ruterbusch J, Heilbrun LK (2014) Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men. Cancer Epidemiol Biomark Prev 23:1505–1511CrossRef Powell IJ, Vigneau FD, Bock CH, Ruterbusch J, Heilbrun LK (2014) Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men. Cancer Epidemiol Biomark Prev 23:1505–1511CrossRef
27.
go back to reference Murphy AB, Bhatia R, Martin IK et al (2014) Are HIV-infected men vulnerable to prostate cancer treatment disparities? Cancer Epidemiol Biomark Prev 23:2009–2018CrossRef Murphy AB, Bhatia R, Martin IK et al (2014) Are HIV-infected men vulnerable to prostate cancer treatment disparities? Cancer Epidemiol Biomark Prev 23:2009–2018CrossRef
28.
go back to reference Simon Rosser BR, Merengwa E, Capistrant BD, Iantaffi A, Kilian G, Kohli N, Konety BR, Mitteldorf D, West W (2016) Prostate cancer in gay, bisexual, and other men who have sex with men: a review. LGBT Health 3:243CrossRef Simon Rosser BR, Merengwa E, Capistrant BD, Iantaffi A, Kilian G, Kohli N, Konety BR, Mitteldorf D, West W (2016) Prostate cancer in gay, bisexual, and other men who have sex with men: a review. LGBT Health 3:243CrossRef
29.
go back to reference Becker JT, Kingsley LA, Molsberry S et al (2014) Cohort profile: recruitment cohorts in the neuropsychological substudy of the multicenter AIDS cohort study. Int J Epidemiol 44:1506–1516CrossRefPubMedPubMedCentral Becker JT, Kingsley LA, Molsberry S et al (2014) Cohort profile: recruitment cohorts in the neuropsychological substudy of the multicenter AIDS cohort study. Int J Epidemiol 44:1506–1516CrossRefPubMedPubMedCentral
30.
go back to reference Seaberg EC, Wiley D, Martinez-Maza O et al (2010) Cancer incidence in the multicenter AIDS cohort study before and during the HAART era: 1984 to 2007. Cancer 116:5507–5516CrossRefPubMedPubMedCentral Seaberg EC, Wiley D, Martinez-Maza O et al (2010) Cancer incidence in the multicenter AIDS cohort study before and during the HAART era: 1984 to 2007. Cancer 116:5507–5516CrossRefPubMedPubMedCentral
32.
34.
go back to reference Giovannucci E, Rimm EB, Liu Y et al (2003) Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst 95:1240–1244CrossRefPubMed Giovannucci E, Rimm EB, Liu Y et al (2003) Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst 95:1240–1244CrossRefPubMed
35.
go back to reference Brawer MK (2003) Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring. Rev Urol 5(Suppl 1):S29–S33PubMedPubMedCentral Brawer MK (2003) Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring. Rev Urol 5(Suppl 1):S29–S33PubMedPubMedCentral
37.
go back to reference Hartman ME, Irvine J, Currie KL et al (2014) Exploring gay couples’ experience with sexual dysfunction after radical prostatectomy: a qualitative study. J Sex Marital Ther 40:233–253CrossRefPubMed Hartman ME, Irvine J, Currie KL et al (2014) Exploring gay couples’ experience with sexual dysfunction after radical prostatectomy: a qualitative study. J Sex Marital Ther 40:233–253CrossRefPubMed
38.
go back to reference Hart TL, Coon DW, Kowalkowski MA et al (2014) Changes in sexual roles and quality of life for gay men after prostate cancer: challenges for sexual health providers. J Sex Med 11:2308–2317CrossRefPubMedPubMedCentral Hart TL, Coon DW, Kowalkowski MA et al (2014) Changes in sexual roles and quality of life for gay men after prostate cancer: challenges for sexual health providers. J Sex Med 11:2308–2317CrossRefPubMedPubMedCentral
39.
go back to reference Perlman G (2005) Prostate cancer, the group, and me. J Gay Lesbian Psychother 9:69–90CrossRef Perlman G (2005) Prostate cancer, the group, and me. J Gay Lesbian Psychother 9:69–90CrossRef
40.
go back to reference Simon Rosser BR, Merengwa E, Capistrant BD et al (2016) Prostate cancer in gay, bisexual, and other men who have sex with men: a review. LGBT Health 3:32–41PubMedCentral Simon Rosser BR, Merengwa E, Capistrant BD et al (2016) Prostate cancer in gay, bisexual, and other men who have sex with men: a review. LGBT Health 3:32–41PubMedCentral
41.
go back to reference Carter BS, Bova GS, Beaty TH et al (1993) Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150:797–802PubMed Carter BS, Bova GS, Beaty TH et al (1993) Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150:797–802PubMed
Metadata
Title
Racial differences in prostate cancer risk in young HIV-positive and HIV-negative men: a prospective cohort study
Authors
Anupriya Dutta
Hajime Uno
Alex Holman
David R. Lorenz
Dana Gabuzda
Publication date
01-07-2017
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 7/2017
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-017-0896-9

Other articles of this Issue 7/2017

Cancer Causes & Control 7/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine